Fate Therapeutics, Inc. (NASDAQ: FATE) announced the appointment of Laura Hamill to its board of directors. Hamill brings more than three decades of commercial and strategic management experience in the biopharmaceutical industry.

Hamill most recently served as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc., where she oversaw approximately $22 billion in annual revenue and managed an organization of 2,500 employees. Prior to Gilead, she spent nearly two decades at Amgen, where she held roles of increasing responsibility in the United States and internationally.

At Amgen, Hamill served as Senior Vice President, U.S. Commercial Operations, overseeing the business unit representing roughly 80% of company revenue and 2,000 employees across multiple divisions. She currently serves on the boards of BB Biotech AG and Jazz Pharmaceuticals.

"Laura brings a breadth of global commercial and management experience and has demonstrated continued success over her career," said Bob Valamehr, President and Chief Executive Officer of Fate Therapeutics. "Her insight and operational expertise will be highly valuable as we advance our pipeline toward later-stage development and prepare for commercialization."

Fate Therapeutics is a clinical-stage biopharmaceutical company developing induced pluripotent stem cell-derived cellular immunotherapies for patients with cancer and autoimmune diseases. The company uses its iPSC product platform to create off-the-shelf cell products.

Hamill holds a Bachelor of Business Administration with an emphasis in marketing from the University of Arizona. The information is based on a company press release statement.